Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lixte Biotechnology Holdings has announced that the National Institute of Neurological Disorders and Stroke, National Institutes of Health and Lixte have filed a joint patent application for a new cancer biomarker.
Subscribe to our email newsletter
The new biomarker, present in many common cancers, is a target of drugs being evaluated by Lixte and the National Institute of Neurological Disorders and Stroke (NINDS) for the treatment of brain tumors.
John Kovach, president and CEO of Lixte, said: “Studies with the research team at the molecular pathogenesis unit, surgical neurology branch, NINDS, identified a biomarker that appears to be preferentially targeted by novel anticancer drugs currently being evaluated by NINDS and Lixte as new treatments for human brain tumors.
“Molecular studies revealed that these drugs alter the state of this biomarker in a way that leads to the death of cancer cells. Since the biomarker appears to be important to the survival of several human cancers in addition to brain cancers, studies will be done to determine the effectiveness of targeting the biomarker in other tumor types and as a guide to drug discovery of new anticancer compounds.”